San Francisco Business Times reports on local biotechs’ latest IPO moves.
Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others.
Zosano is advancing a pipeline of drug candidates based on the ZP Patch Technology – a proprietary transdermal delivery technology capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin’s outer layer and ensuring significant and rapid therapeutic effect.
Intersect ENT is a health care equipment company based in Menlo Park, California. It manufactures drug-delivery devices used by Ear, Nose & Throat clinicians in the treatment of sinusitis